Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3473329 · 5 trials · 3 indications
Least Squares Mean (LS Mean) was calculated using a Mixed Model for Repeated Measures (MMRM): Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
Part 2: PK: F of LY3473329
PK: AUC0-∞ of LY3473329
PK: AUC0-tlast of LY3473329
PK: Cmax of LY3473329
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| 10 mg LY3473329 | EXPERIMENTAL | Participants received 10 milligrams (mg) of LY3473329 administered orally once daily (QD) over a 12-week treatment period. |
| 60 mg LY3473329 | EXPERIMENTAL | Participants received 60 mg of LY3473329 administered orally QD over a 12-week treatment period. |
| 240 mg LY3473329 | EXPERIMENTAL | Participants received 240 mg of LY3473329 administered orally QD over a 12-week treatment period. |
| Placebo | PLACEBO_COMPARATOR | Participants received a matching dose of placebo administered orally QD over a 12-week treatment period. |
| [14C]-LY3473329 (Part 1) | EXPERIMENTAL | Single dose of \[¹⁴C\]-LY3473329 administered orally |
| LY3473329 + [14C]-LY3473329 (Part 2) | EXPERIMENTAL | Single dose of LY3473329 administered orally followed by a single dose of \[¹⁴C\]-LY3473329 administered intravenously (IV) |
| LY3473329 (Control) | EXPERIMENTAL | LY3473329 administered orally to participants with normal renal function |
| LY3473329 (Mild Renal Impairment) | EXPERIMENTAL | LY3473329 administered orally to participants with mild renal impairment |
| LY3473329 (Moderate Renal Impairment) | EXPERIMENTAL | LY3473329 administered orally to participants with moderate renal impairment |
| LY3473329 (Severe Renal Impairment) | EXPERIMENTAL | LY3473329 administered orally to participants with severe renal impairment |
| LY3473329 (End-Stage Renal Disease) | EXPERIMENTAL | LY3473329 administered orally to participants with end-stage renal disease |
| LY3473329 | EXPERIMENTAL | LY3473329 administered orally. |
| LY3473329 (Part A) | EXPERIMENTAL | LY3473329 administered orally. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered orally. |
| LY3473329 (Part B) | EXPERIMENTAL | LY3473329 administered orally. |
| Placebo (Part B) | EXPERIMENTAL | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| LY3473329 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| [14C]-LY3473329 | DRUG | Administered orally |
Inclusion Criteria: * Participants must be at least 40 years old * Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory. * High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atheroscler...
LY3473329 is an investigational small molecule being studied for use in healthy participants, in people with renal insufficiency, and in adults with elevated lipoprotein(a) who are at high risk for cardiovascular events. It is being developed by Eli Lilly and Company and is currently in clinical development.
LY3473329 is a small molecule being studied for its effects on lipoprotein(a) levels. It is being investigated in adults with elevated lipoprotein(a) who are at high risk for cardiovascular events, suggesting it targets pathways related to lipoprotein(a) metabolism.
LY3473329 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
LY3473329 is in Phase 2 clinical development. It has completed Phase 1 trials in healthy participants and a Phase 2 trial in adults with elevated lipoprotein(a) at high risk for cardiovascular events. The drug is investigational and has not been approved by regulatory authorities.
LY3473329 has completed several clinical trials, including NCT04472676 and NCT05038787 in healthy participants, NCT05563246 in adults with elevated lipoprotein(a), and NCT06342596 in healthy male participants. These trials were conducted in multiple countries, including the United States, Netherlands, and Japan.
LY3473329 is the primary identifier for this investigational drug. No alternative names have been reported for this compound. It is being studied under this designation in clinical trials registered with ClinicalTrials.gov.